Mission and Goal
The fundamental mission of KoDiscovery is to complete the necessary research, including human clinical trials, to make 3-Bromopyruvate (3BP) therapy available for all people with cancer. To further define and differentiate her discovery, Dr. Ko has designated her patented formulation, now over 20 years in development, as KoDiscovery Anticancer Technology, or KAT. Our broader mission, therefore, is to support the development of treatments and cures for multiple types of cancer, neurological diseases, and other devastating disorders for which no effective therapies are yet known. Ultimately, our mission is to provide relief to those suffering from any health issue, including malnutrition, illness, poverty, lack of basic needs, and other health and human needs that are prevalent around the world.
The goal of KoDiscovery is to become a world leader in the research and delivery of innovative therapies in the field of advanced metabolic and cellular diseases. We will work diligently to ensure that all people with cancer and neurodegenerative diseases have access to the best medical treatments available.
During the spring of 2022, KoDiscovery & NewG Lab Pharma prepare for our first clinical trial, having received FDA approval for a phase I/II A study for primary liver cancer.
Our current focus is to expedite evidence & research based cancer therapeutics from bench to bedside.
In keeping with our goal to develop effective nutritional support for chronic health issues, 2021 saw the development and manufacture of three new KOfactor® supplements.
These proprietary supplement formulations are researched and developed by Dr. Ko with the same rigor as her pharmaceuticals.
KoDiscovery and NewG Lab Pharma are currently working on multiple initiatives to lead the development of
various anticancer therapeutics.
Our comprehensive approach includes multiple anticancer drug therapeutics, biomarker development, nutritional support, adjunctive treatment with existing therapies & pet cancer treatments.
Based on our preliminary work and success with several animals we anticipate developing a regimen and protocols for convenient KAT administration for pets.
Administering safe, effective and affordable anticancer therapies for pets presents unique challenges. Our recent success with Kozmo is guiding our KAT pipeline for pets.